Given the dysfunctional role of SOD enzymes in Alzheimer’s disease, it is possible that an infusion of Tregs would have a limited effect as they become unstable from ROS, and it may be necessary to measure the antioxidant status of patients with Alzheimer’s disease before administering these novel treatments. The gene discussed is SOD1; the disease is early-onset autosomal dominant Alzheimer disease.